AAP
PRLD icon

Arax Advisory Partners’s Prelude Therapeutics PRLD Stock Holding History

Arax Advisory Partners’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15
Closed -$22 – 4435
2025
Q3 		$22 Buy
+15
New +$15 ﹤0.01% 3571
2024
Q4 		– Sell
-19
Closed -$40 – 2675
2024
Q3 		$40 Hold
19
– – ﹤0.01% 2593
2024
Q2 		$73 Buy
+19
New +$77 ﹤0.01% 2506

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arax Advisory Partners's PRLD Position: Q4 2025 in Review

Arax Advisory Partners sold out of Prelude Therapeutics (PRLD) in Q4 2025, closing a stake of 15 shares — an estimated $22 sold.

Arax Advisory Partners first reported a position in PRLD in Q2 2024 and held it in 3 quarters. The position peaked at $73 in Q2 2024. 48 funds tracked by Wall St. Rank hold PRLD as of Q4 2025.

  • Arax Advisory Partners reported no remaining Prelude Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 15 Prelude Therapeutics shares in Q4 2025, an estimated $22.
  • Arax Advisory Partners first reported a position in Prelude Therapeutics in Q2 2024 and held it in 3 quarters.
  • Arax Advisory Partners's Prelude Therapeutics position peaked at $73 in Q2 2024.
  • 48 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.